The Pneumoconiosis Market Size was valued at USD 3.19 Billion in 2023. The Global Pneumoconiosis industry is projected to grow from USD 3.44 Billion in 2024 to USD 6.37 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 8.60% during the forecast period (2024 - 2032). Pneumoconiosis is a restrictive and occupational lung disease caused by inhalation of dust. There are a number of different agents that, when inhaled, can potentially cause pneumoconiosis. Organic and inorganic agents are responsible for causing this diseases.
As per a report published in 2024, an announcement made by an official of the National Health Commission informed that China opened 829 sites for the free treatment of patients suffering from pneumoconiosis, which is said to have accounted for nearly 90% of all cases reported as occupational diseases in China, Wang Jiandong, Vice-director of NHC Department of Occupational Health told a press conference. This is an important step, marking a critical awareness in the management of the disease by the Chinese Government.
Dr Samit Sharma has disclosed that an Artificial Intelligence (AI) based application has been developed to facilitate silicosis certification processes in the new Silicosis Portal at the DPB level, as per the report published in 2024. The function was started by Rajasthan's Minister of Social Justice and Empowerment, Tikaram Julie. The AI-supported system for silicosis screening is reflective of the government’s progressive stance towards applying technology to expedite medical delivery and economic support targeted at those who are most vulnerable.
Rajasthan became the first state to implement a silicosis policy for the welfare of mining workers, including BOCW, with the implementation of the Rajasthan Pneumoconiosis Policy-2019 by the state government.
Among them, pneumoconiosis is one such disease that is very common all over the world, especially developing countries, where there were 81.1% more cases from 1990 to 2017 for both males and females. In males, the age-adjusted prevalence ratio was found to be significantly higher than in females.
According to a Global Burden Disease study in 2010, pneumoconiosis caused approximately 125000 deaths. According to Global Burden Disease, there were about 3495 deaths due to asbestosis. The tendency among dust-exposed workers revealed an increasing prevalence of pneumoconiosis. Jiangsu Province, China, had a record number as it registered about 9,243 between 2006 and 2017, with most of those suffering from Silicosis and coal worker pneumoconiosis.
According to the Centers for Disease Control and Prevention, in 2013, 260,000 deaths occurred due to pneumoconiosis. Increasing prevalence of pneumoconiosis, increasing smoking population, and rising air pollution have driven the growth of the market. Approximately 75% of non-asbestos pneumoconiosis cases recorded under the IIDB scheme in 2009 were from individuals that are over 65 years.
According to the Centers for Disease Control and Prevention, cigarette smoking is the leading cause of death in the United States, accounting for over 480,000 deaths every year. Moreover, increasing geriatric population, increasing healthcare expenditure, and strong encouragement from the government have also contributed to the growth of the market. According to research, smoking increases the possibility of pneumoconiosis; more than 60% of the global population smokes, this has increased the risk of pneumoconiosis and contributed in the growth of the market. However, side effects associated with the treatment and lack of long term treatment may lead to hinder the growth of the market.
The pneumoconiosis market is segmented on the basis of types, causes, therapy, and end users.
On the basis of types, the pneumoconiosis market is segmented into asbestosis, berylliosis, byssinosis, coal workers pneumoconiosis, silicosis, and others.
On the basis of causes, the pneumoconiosis market is categorised into organic dusts, non-organic substances, and others. Organic substances are further segmented into hay, malt, mushrooms, and others. Non organic substances are further segmented into sulphur dioxide, ammonia, nitrogen dioxide, and others.
On the basis of therapy, the pneumoconiosis market is segmented into diagnosis, and treatment. Diagnosis is further segmented into chest X-ray, CT scan, and others. Treatment is further classified into mucolytic agent, antibiotic, and others.
On the basis of end users, the pneumoconiosis market is segmented into hospital, clinics, and others.
America dominates the pneumoconiosis market owing to large patient population. Apart from this, increasing number of patients, changing lifestyle and increasing healthcare expenditure have boosted the growth of the market in America. According to the Centers for Disease Control and Prevention, in 2015, about 15 in every 100 U.S. adults aged over 18 years smoked cigarettes. Which is equals around 36.5 million adults in the United States currently smoke cigarettes. Increasing smoking population increases the possibility of causing the disease. Additionally, increasing awareness among the people regarding different diagnostic procedures and well-developed technology has also contributed to the growth of the market.
Europe is the second largest pneumoconiosis market, which is followed by Asia Pacific. Huge smoking population, availability of funds for research, and government support for research & development will drive the market.
Asia Pacific is the fastest growing region for the market due to the presence of a huge patient population, continuously developing economies, and presence of huge opportunity in the market.
On the other hand, the Middle East & Africa has the least share in the pneumoconiosis market due to presence of poor economy especially in Africa region. Majority of the market of this region is held by Middle East due to well-developed healthcare sector and huge healthcare expenditure.
The key players for the pneumoconiosis market
Intended Audience
| Report Attribute/Metric | Details |
| Market Size 2032 | Â USD 6.37 Billion |
| CAGR | Â Â 8.60% (2024-2032) |
| Base Year | Â Â 2023 |
| Forecast Period | Â 2024-2032 |
| Historical Data | Â Â 2020 |
| Forecast Units | Â Â Value (USD Billion) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Types, Causes, Therapy, and End Users |
| Geographies Covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
| Key Vendors | Abbott (US) Eli Lilly (U.S.), Sunpharma (India), Sanofi (France), Novo Nordisk (Denmark), Novartis (Switzerland), Abbott (U.S.), AstraZeneca (U.K), Merck & Co. (U.S.), Pfizer (U.S.), Svizera Healthcare (India), F. Hoffman La Roche AG (Germany), and Bayer Cropscience Ltd. (U.S.) |
| Key Market Opportunities | Increasing geriatric populationIncreasing healthcare expenditureStrong encouragement from the government |
| Key Market Drivers | Increasing prevalence of pneumoconiosis Increasing smoking population Rising air pollution |
Pneumoconiosis Market Highlights:
Frequently Asked Questions (FAQ) :
Pneumoconiosis market is projected to grow at a 8.60% CAGR between 2024-2032.
The Americas is expected to dominate the pneumoconiosis market.
Non-organic substances, organic dusts, and others are the major causes of pneumoconiosis.
Lack of long term treatment and certain side effects are factors that may limit the pneumoconiosis market growth.
Leading players profiled in the pneumoconiosis market include Bayer Cropscience Ltd. (U.S.), F. Hoffman La Roche AG (Germany), Svizera Healthcare (India), Pfizer (U.S.), Merck & Co. (U.S.), AstraZeneca (U.K), Abbott (U.S.), Novartis (Switzerland), Novo Nordisk (Denmark), Sanofi (France), Sunpharma (India), Sunpharma (India), and Abbott (US) Eli Lilly (U.S.).
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
